Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
porcine interferon
- Development stage
- Unknown
- Lead developer
- Center for Foot-and-Mouth Disease Vaccine Research
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Porcine interferon (pIFN) is a cytokine derived from pigs, belonging to the interferon family known for its crucial role in innate immunity. It exhibits antiviral, antitumor, and immunomodulatory properties. Its mechanism involves binding to specific cell surface receptors, primarily the interferon alpha/beta receptor (IFNAR) for type I interferons, which subsequently activates the JAK-STAT signaling pathway. This activation leads to the transcription of numerous interferon-stimulated genes (ISGs), establishing an antiviral state and modulating immune responses. Historically and commonly, porcine interferon has been utilized in veterinary medicine to combat various viral infections in swine, such as African swine fever, porcine reproductive and respiratory syndrome, and transmissible gastroenteritis. However, it is also being investigated in human clinical trials, specifically in combination with DOC1021 for the treatment of newly diagnosed adult glioblastoma.
- Other names
- pIFNPoIFN-αPoIFN-γswine interferon
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on porcine interferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on porcine interferon.